Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

November 23, 2011

A Focus on Life Sciences

Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that…

Posted by James A. Datin

November 15, 2011

Opportunity in the Migraine Market for NuPathe

Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that…

Posted by James A. Datin

November 8, 2011

The Developing Pet Generics Market: A Look at New Partner Company Putney

In America, there are more than 171 million dogs and cats in over 71 million households. Ninety-six percent of the drugs approved for these pets…

Posted by James A. Datin

September 1, 2011

NuPathe: FDA CRL Doesn’t Reject NDA or Impact Potential Long-Term Value, Only Delays Launch

The line between long-term value creation and short-term speculative trading was never as stark as it was this week on Tuesday, August 30, after life…

Posted by John E. Shave III

July 27, 2011

Safeguard Scientifics Second Quarter 2011 Financial Results Recap

This morning, we announced our second quarter 2011 financial results and reported on the exciting progress we’ve made this quarter. We deployed $45.8 million of…

Posted by John E. Shave III

March 3, 2011

Safeguard Scientifics Fourth Quarter and Year-End Financial Results Recap, Highlighting Aggregate Partner Company Revenue Growth, Acquisitions and IPOs

This morning, we announced our fourth quarter and year-end 2010 financial results. In 2010, our aggregate partner company revenue was $403 million, up 54 percent…

Posted by John E. Shave III

January 19, 2011

Life Sciences Trends for 2011: Companion Diagnostics, Reimbursement and Consumerization

Last week, Safeguard Scientifics’ Life Sciences team attended J.P. Morgan’s 29th Annual Healthcare Conference and OneMedForumSF 2011 (video) in San Francisco. Our main takeaway is that…

Posted by James A. Datin

November 1, 2010

NuPathe Submits Zelrix NDA for the Treatment of Migraine

Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…

Posted by James A. Datin

February 23, 2010

An Overview of Our Partner Companies

Safeguard Scientifics’ strategy is to deploy capital in growth-stage companies in attractive sectors of the life sciences and technology industries. Within life sciences, we target…

Posted by Stephen T. Zarrilli